Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations.
Tefferi
Ayalew
A
Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA. tefferi.ayalew@mayo.edu
Passamonti
Francesco
F
D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007370:Interferon Type I / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D011248:Pregnancy Complications / Q000209:etiology / Q000517:prevention & control*; D011256:Pregnancy Outcome; D011994:Recombinant Proteins; D013920:Thrombocythemia, Essential / Q000150:complications / Q000188:drug therapy*
D006495:Heparin, Low-Molecular-Weight; D007370:Interferon Type I; D011994:Recombinant Proteins; D001241:Aspirin; D006918:Hydroxyurea